Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Drug Official Sentenced to Four Years in Prison for Taking Bribes (China)

This article was originally published in PharmAsia News

Executive Summary

Zheng Shangjin, previously chief of Zhejiang Provincial Food and Drug Bureau, has been convicted of taking bribes and sentenced to four years in prison by the Yantian District Court in Shenzhen City, south China's Guangdong Province. Shangjin once arranged a meeting between Tang Xudong, president of Kangliyuan Group, his brother Tang Xiaodong, and Zheng Xiaoyu, former director of China's State Food and Drug Administration (SFDA), when the former SFDA chief was in Zhejiang to attend a local fair. He also used his influence to obtain other benefits for the company, according to the court, which also said that as a government official, Shangjin abused his power and accepted bribes totaling 680,000 yuan from the Tang brothers on two separate occasions. (Click here for more - May Require Free Registration
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066556

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel